TRAVERE THERAPEUTICS, INC. Induced Conversion of Convertible Debt Expense
TRAVERE THERAPEUTICS, INC. (TVTX) reported Induced Conversion of Convertible Debt Expense of $40.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. induced conversion of convertible debt expense for the quarter ending 2026-06-30 was $40.01M.
- TRAVERE THERAPEUTICS, INC. induced conversion of convertible debt expense for the quarter ending 2025-06-30 was $0.00.
| Period end | Induced Conversion of Convertible Debt Expense 3 month | Induced Conversion of Convertible Debt Expense 6 month |
|---|---|---|
| 2026-06-30 | $40.01M 10-Q · filed 2026-08-04 | $40.01M 10-Q · filed 2026-08-04 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |